Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relugolix tablets for heavy menstrual bleeding associated with uterine fibroids
CTR20240199Phase 3Completed
- Sponsor
- Shanghai Huilun Pharmaceutical Co., Ltd.
- Start
- Jan 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of tissue-plasminogen activator in Fibromyoma (LM), hypermenorrhea, sponsored by Shanghai Huilun Pharmaceutical Co., Ltd.. Started Jan 2024; status: completed.
02
Drugs
tissue-plasminogen activator
03
Conditions
Fibromyoma (LM)hypermenorrhea
Beyond the preview
Go deeper on CTR20240199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240199.